SIGA Share Price

Open 2.82 Change Price %
High 3.34 1 Day 0.36 12.46
Low 2.82 1 Week 0.73 28.97
Close 3.25 1 Month 1.27 64.14
Volume 357780 1 Year 1.20 58.54
52 Week High 3.34
52 Week Low 0.60
SIGA Important Levels
Resistance 2 3.73
Resistance 1 3.53
Pivot 3.14
Support 1 2.97
Support 2 2.77
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

SIGA Technologies Inc. (NASDAQ: SIGA)

SIGA Technical Analysis 5
As on 2nd Dec 2016 SIGA Share Price closed @ 3.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.85 & Strong Buy for SHORT-TERM with Stoploss of 2.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
SIGA Target for December
1st Target up-side 3.14
2nd Target up-side 3.5
3rd Target up-side 3.86
1st Target down-side 2.1
2nd Target down-side 1.74
3rd Target down-side 1.38
SIGA Other Details
Segment EQ
Market Capital 152333136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.siga.com
SIGA Address
SIGA
660 Madison Avenue
Suite 1700
New York, NY 10065
United States
Phone: 212-672-9100
Fax: 212-697-3130
Interactive Technical Analysis Chart SIGA Technologies Inc. ( SIGA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on SIGA Technologies Inc.
SIGA Business Profile
SIGA Technologies, Inc. (SIGA) is a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Its business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. The Company's focuses to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. The Company�s product include ST-246, is an orally administered antiviral drug that targets orthopoxviruses. The Company�s lead product, ST-246, is an orally administered antiviral drug that targets orthopoxviruses. On May 13, 2011, it signed the BARDA Contract pursuant to which it agreed to deliver two million courses of ST-246 to the Strategic Stockpile.